Importance of Testing
PD-L1 expression is common in patients with mNSCLC
Find out how many patients with mNSCLC in your practice may express PD-L1 using the Prevalence Calculator.
PD-L1 expression may predict response to immunotherapy in mNSCLC1-5
PD-L1 expression in a biopsy sample may range from <1% to 100%6,†
Reproduced with permission from Massard et al.5
†IHC staining and scoring of PD-L1 expression in NSCLC tumor tissue using the Dako PD-L1 IHC 22C3 pharmDx assay. Image reproduced with permission from Sorensen SF et al 2016.
†IHC staining and scoring of PD-L1 expression in NSCLC tumor tissue using the Dako PD-L1 IHC 22C3 pharmDx assay. Image reproduced with permission from Sorensen SF et al 2016.
Patients with PD-L1 expression may have a better response to anti–PD-1/PD-L1 therapy.1-5
PD-L1 expression may determine eligibility for treatment with immunotherapy in mNSCLC7:
PD-L1 expression may determine eligibility for treatment with immunotherapy in mNSCLC7:
EGFRm tumors may also overexpress PD-L18
~40% of patients with EGFR WT NSCLC may also express PD-L1.8
In newly diagnosed patients with mNSCLC, NCCN Guidelines® recommend PD-1/PD-L1 inhibitor monotherapy or combined with chemotherapy for patients with positive PD-L1 expression (≥50%) and negative or unknown EGFR or ALK mutation status.9,‡
‡Refer to the NCCN Guidelines for specific treatment recommendations for each setting. Not all agents in a drug class are recommended for all settings.
ALK, anaplastic lymphoma kinase; BRAF, v-Raf murine sarcoma viral oncogene homolog B; EGFRm, epidermal growth factor receptor mutation–positive; IHC, immunohistochemistry; mNSCLC, metastatic non–small cell lung cancer; NCCN, National Comprehensive Cancer Network; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1; ROS1, ROS proto-oncogene 1, receptor tyrosine kinase; WT, wild type.
References: 1. Borghaei H et al. N Engl J Med. 2015;373(17):1627-1639. 2. Garon EB et al. N Engl J Med. 2015;372(21):2018-2028. 3. Herbst RS et al. Nature. 2014;515(7528):563-567. 4. Herbst RS et al. Lancet. 2016;387(10027):1540-1550. 5. Fehrenbacher L et al; POPLAR Study Group. Lancet. 2016;387(10030):1837-1846. 6. Sorensen SF et al. Transl Oncol. 2016;9(1):64-69. 7. Keytruda® (pembrolizumab) [prescribing information]. Whitehouse Station, NJ: Merck and Co., Inc.; 2018. 8. D'Incecco A et al. Br J Cancer. 2015;112(1):95-102. 9. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Non–Small Cell Lung Cancer V3.2019. © National Comprehensive Cancer Network, Inc. 2019. All rights reserved. Accessed January 31, 2019. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. To view the most recent and complete version of the guideline, go online to NCCN.org.
Trademarks are the property of their respective owners.
